

# Guard Therapeutics appoints Ann-Kristin Myde as Head of Global Project Management

**Guard Therapeutics today announces that Ann-Kristin Myde has been appointed new Head of Global Project Management for the company. She will take up her post on 1 April 2021.**

Ann-Kristin Myde has a B.Sc. in Biochemistry from Stockholm University and more than 30 years' experience from the pharmaceutical industry, where she has held a number of senior positions in project management, business development and marketing at industry-leading players such as AstraZeneca and Thermo Fisher. Before joining Guard Therapeutics, she worked at Calliditas Therapeutics where she was in charge of clinical development and project management in renal medicine. As Head of Global Project Management, Ann-Kristin Myde will be part of Guard Therapeutics' management team and report to the company's CEO.

"I am very happy to welcome Ann-Kristin Myde to Guard Therapeutics. She has extensive knowledge from some of the world's largest pharmaceutical companies and will bring very valuable expertise to Guard Therapeutics, especially in the form of experience from developing treatments for kidney failure. I look forward to working with Ann-Kristin on the continued clinical development of our investigational drug ROSgard," Tobias Agervald, CEO of Guard Therapeutics, says.

Guard Therapeutics' investigational drug ROSgard has been shown in preclinical studies to protect against cell and organ damage, including acute kidney injury, by counteracting oxidative stress and supporting regenerative processes. Several phase 1 studies have been completed with positive outcomes and the company is now preparing an initial study in the primary target group for treatment – patients undergoing heart surgery with a high risk of developing acute kidney injury.

**For further information, please contact:**

---

## **Tobias Agervald, CEO**

Telephone: +46 46 286 50 30

E-mail: [info@guardtherapeutics.com](mailto:info@guardtherapeutics.com)

## **About Guard Therapeutics**

---

Guard Therapeutics' investigational drug ROSgard has been documented in several preclinical studies to protect against cell and organ damage, including acute kidney damage, by counteracting oxidative stress and supporting regenerative processes. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

Press Release  
28 December 2020 12:00:00 CET

---



## Attachments

---

[Guard Therapeutics appoints Ann-Kristin Myde as Head of Global Project Management](#)